Progress in the mechanism and drug development of castration-resistant prostate cancer.

Although prostate cancer can initially respond to androgen deprivation therapy, it will inevitably relapse and switch to a castration-resistant state. The progress in understanding the mechanism of castration-resistant prostate cancer (CRPC) has led to the evolution of novel agents, including sipuleucel-T as an immunomodulant agent, enzalutamide as an androgen receptor antagonist, docetaxel as a chemotherapeutic agent and radium-223 as a radiopharmaceutical agent. In this review, we discuss the main mechanisms of CRPC and the development of promising agents along with the novel therapies in the clinic. New therapeutic challenges remain, such as the identification of predictive biomarkers and the optimal combinations of agents. Future investigation is still needed for a better understanding of CRPC.

[1]  M. Gleave,et al.  PARP inhibition in castration-resistant prostate cancer. , 2016, Future oncology.

[2]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[3]  Yezi Zhu,et al.  Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3‐AR axis inhibition , 2015, The Prostate.

[4]  C. V. von Klot,et al.  Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. , 2015, European urology.

[5]  Jun Luo,et al.  Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. , 2015, JAMA oncology.

[6]  J. Palvimo,et al.  Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies , 2015, Scientific Reports.

[7]  Jiaoti Huang,et al.  Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells. , 2015, Oncotarget.

[8]  Martin E. Gleave,et al.  Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. , 2015, European urology.

[9]  T. Tammela,et al.  ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). , 2015 .

[10]  A. Armstrong,et al.  Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). , 2015 .

[11]  D. Dearnaley,et al.  PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate , 2015, European urology.

[12]  D. Dransfield,et al.  Androgen Receptor Modulation Optimized for Response in Splice Variant (ARMOR3-SV): Randomized, open-label, multicenter, controlled study of galeterone versus enzalutamide (enz) in men expressing AR-V7 splice variant (SV), metastatic castrate resistant prostate cancer (mCRPC). , 2015 .

[13]  F. Saad,et al.  Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. , 2015, The Lancet. Oncology.

[14]  G. Raj,et al.  EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer , 2015, Oncotarget.

[15]  V. Njar,et al.  Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. , 2015, Journal of medicinal chemistry.

[16]  B. Dai,et al.  Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer , 2015, Scientific Reports.

[17]  C. Creighton,et al.  Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer. , 2014, The Journal of clinical investigation.

[18]  M. Gleave,et al.  Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer , 2014, Molecular Cancer Therapeutics.

[19]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[20]  E. Heath,et al.  757OGALETERONE IN 4 PATIENT POPULATIONS OF MEN WITH CRPC: RESULTS FROM ARMOR2. , 2014, Annals of Oncology.

[21]  B. Carver.  Strategies for targeting the androgen receptor axis in prostate cancer. , 2014, Drug discovery today.

[22]  E. Antonarakis,et al.  Clinical activity of enzalutamide versus docetaxel in men with castration‐resistant prostate cancer progressing after abiraterone , 2014, The Prostate.

[23]  E. Shtivelman,et al.  Molecular pathways and targets in prostate cancer , 2014, Oncotarget.

[24]  T. Tammela,et al.  Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. , 2014, The Lancet. Oncology.

[25]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[26]  J. Aragon-Ching,et al.  Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer. , 2014, Cancer biology & therapy.

[27]  M. Loda,et al.  708: A Phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer , 2014 .

[28]  M. Michaelson,et al.  Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen , 2014, Clinical Cancer Research.

[29]  Shihua Sun,et al.  Mechanisms of the androgen receptor splicing in prostate cancer cells , 2014, Oncogene.

[30]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[31]  E. Small,et al.  A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) versus ADT alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC): The SPARTAN trial. , 2014 .

[32]  Yezi Zhu,et al.  Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.

[33]  E. Wiemer,et al.  Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. , 2013, European journal of cancer.

[34]  P. Stephens,et al.  Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary , 2013, Clinical Cancer Research.

[35]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[36]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[37]  H. Scher,et al.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  A. Armstrong,et al.  Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  R. Andersen,et al.  An androgen receptor N-terminal domain antagonist for treating prostate cancer. , 2013, The Journal of clinical investigation.

[40]  J. Bono,et al.  Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  J. Chan,et al.  Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? , 2013, Urologic oncology.

[42]  P. Purushottamachar,et al.  Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. , 2013, Journal of medicinal chemistry.

[43]  S. Hotte,et al.  Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). , 2013 .

[44]  V. Arora,et al.  Overcoming mutation-based resistance to antiandrogens with rational drug design , 2013, eLife.

[45]  M. Gleave,et al.  Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo , 2013, Molecular Cancer Therapeutics.

[46]  R. Ferraldeschi,et al.  Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer , 2013, Clinical Cancer Research.

[47]  H. Scher,et al.  ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Jun Luo,et al.  Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. , 2013, Cancer research.

[49]  R. Pili,et al.  Tasquinimod: A Novel Angiogenesis Inhibitor–Development in Prostate Cancer , 2013, Current Oncology Reports.

[50]  J. Bono,et al.  Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[52]  Michael Moser,et al.  Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression. , 2012, Biochemical and biophysical research communications.

[53]  J. Carles,et al.  Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen , 2012 .

[54]  H. Scher,et al.  ARN-509: a novel antiandrogen for prostate cancer treatment. , 2012, Cancer research.

[55]  H. Scher,et al.  Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. , 2012, European urology.

[56]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Paul Workman,et al.  Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? , 2012, Clinical Cancer Research.

[58]  W. Sellers,et al.  Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor , 2011, Molecular Cancer Therapeutics.

[59]  P. Ditonno,et al.  Androgen deprivation therapy affects BCL-2 expression in human prostate cancer. , 2011, International journal of oncology.

[60]  T. Hitaka,et al.  Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. , 2011, Bioorganic & medicinal chemistry.

[61]  W. Isaacs,et al.  A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities , 2011, The Prostate.

[62]  A. Armstrong,et al.  Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  M. Gleave,et al.  Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. , 2011, Journal of medicinal chemistry.

[64]  K. Spindler,et al.  Inability of NCoR/SMRT to repress androgen receptor transcriptional activity in prostate cancer cell lines. , 2011, International journal of molecular medicine.

[65]  W. Oh,et al.  Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. , 2011, Urology.

[66]  Rui Li,et al.  Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[67]  L. Tran,et al.  Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. , 2011, Cancer cell.

[68]  C. Logothetis,et al.  Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC). , 2011, Journal of Clinical Oncology.

[69]  M. Gleave,et al.  728 AZD5363, A NOVEL AKT INHIBITOR, DELAYS PROSTATE CANCER PROGRESSION , 2011 .

[70]  E. Antonarakis,et al.  Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer , 2011, Drug design, development and therapy.

[71]  J. Baselga,et al.  Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer , 2011, Molecular Cancer Therapeutics.

[72]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[73]  I. Tannock,et al.  Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  S. Koochekpour,et al.  Androgen receptor signaling and mutations in prostate cancer. , 2010, Asian journal of andrology.

[75]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[76]  David E. Williams,et al.  Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. , 2010, Cancer cell.

[77]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[78]  C. Sawyers,et al.  Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). , 2010, Journal of medicinal chemistry.

[79]  P. Kantoff,et al.  Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  M. Gorospe,et al.  Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer , 2010, Nucleic acids research.

[81]  C. Cordon-Cardo,et al.  Androgen receptor expression is associated with prostate cancer‐specific survival in castrate patients with metastatic disease , 2010, BJU international.

[82]  K. Waltering,et al.  Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. , 2009, Cancer research.

[83]  Johann S de Bono,et al.  Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer , 2009, Clinical Cancer Research.

[84]  M. Gleave,et al.  Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[85]  R. Madan,et al.  Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer , 2009, Expert opinion on investigational drugs.

[86]  S. Dhanasekaran,et al.  Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. , 2009, Cancer research.

[87]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[88]  B. Somer,et al.  An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer , 2009, Clinical Cancer Research.

[89]  Jonathan Melamed,et al.  LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. , 2009, Cancer research.

[90]  Zhiyong Guo,et al.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.

[91]  F. Sarkar,et al.  A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer , 2008, Clinical Cancer Research.

[92]  Mitch Dowsett,et al.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[94]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[95]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[96]  David G. I. Kingston,et al.  Tubulin-interactive natural products as anticancer agents. , 2008, Journal of natural products.

[97]  J. Bartlett,et al.  Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients , 2008, British Journal of Cancer.

[98]  K. Pienta,et al.  In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. , 2007, Neoplasia.

[99]  C. Tepper,et al.  Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. , 2007, Cancer research.

[100]  D. Troyer,et al.  Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation , 2007, Clinical Cancer Research.

[101]  Jie Ge,et al.  Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 , 2006, Proceedings of the National Academy of Sciences.

[102]  E. Walker-Corkery,et al.  The rising prevalence of androgen deprivation among older American men since the advent of prostate‐specific antigen testing: a population‐based cohort study , 2006, BJU international.

[103]  K. Shigeno,et al.  Bcl-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated with Taxane-Based Chemotherapy , 2006, Clinical Cancer Research.

[104]  James R. Porter,et al.  Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. , 2006, Journal of medicinal chemistry.

[105]  A. Hamburger,et al.  The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[106]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[107]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[108]  Desok Kim,et al.  Androgen receptor gene amplification and protein expression in recurrent prostate cancer. , 2003, The Journal of urology.

[109]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[110]  Nicholas Bruchovsky,et al.  Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[111]  L. Morel,et al.  Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. , 2002, The Biochemical journal.

[112]  S. Balk,et al.  Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. , 2002, Molecular endocrinology.

[113]  E. Gelmann,et al.  Molecular biology of the androgen receptor. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  C. Cordon-Cardo,et al.  17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[115]  K. Pienta,et al.  The Current State of Hormonal Therapy for Prostate Cancer , 2002, CA: a cancer journal for clinicians.

[116]  M. Gleave,et al.  Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy , 2002, The Prostate.

[117]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[118]  Tetsurou Matsumoto,et al.  Different expression of androgen receptor coactivators in human prostate. , 2001, Urology.

[119]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[120]  Tony Hunter,et al.  Epidermal Growth Factor-Induced Tumor Cell Invasion and Metastasis Initiated by Dephosphorylation and Downregulation of Focal Adhesion Kinase , 2001, Molecular and Cellular Biology.

[121]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[122]  B. Foster,et al.  Hormone Status Selects for Spontaneous Somatic Androgen Receptor Variants That Demonstrate Specific Ligand and Cofactor Dependent Activities in Autochthonous Prostate Cancer* , 2001, The Journal of Biological Chemistry.

[123]  F. S. French,et al.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.

[124]  K. Makino,et al.  HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. , 2000, Cancer research.

[125]  Peter Scholz,et al.  Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor , 2000, The Journal of Biological Chemistry.

[126]  H. Miyake,et al.  Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. , 2000, Cancer research.

[127]  J. Schleutker,et al.  Androgen receptor gene mutations in hormone‐refractory prostate cancer , 1999, The Journal of pathology.

[128]  A. Belldegrun,et al.  Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. , 1999, Cancer research.

[129]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[130]  J. Isaacs,et al.  The biology of hormone refractory prostate cancer. Why does it develop? , 1999, The Urologic clinics of North America.

[131]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[132]  R J Fletterick,et al.  Structure and specificity of nuclear receptor-coactivator interactions. , 1998, Genes & development.

[133]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[134]  H. Perlman,et al.  Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. , 1995, Cancer research.

[135]  P. Miller,et al.  erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. , 1995, Journal of medicinal chemistry.

[136]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[137]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[138]  Carolyn J. Brown,et al.  Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. , 1989, American journal of human genetics.

[139]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[140]  C. Kollmannsberger,et al.  Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. , 2015, European urology.

[141]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[142]  J. Holmlund,et al.  An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate-resistant prostate cancer (CRPC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  L. Neckers,et al.  The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin , 1998, Cancer Chemotherapy and Pharmacology.